TickerTalks
Browse all tickers →
TickerTalks›$CAH
CACAH

Cardinal Health, Inc.

$CAH·$56B·Medical - Distribution·Healthcare
$253.71+2.4%YTD+24.0%1Y+63.0%
Price updated 11h ago·X counts updated 4d ago
CACAH
$CAHCardinal Health, Inc.
$253.71+2.41%65 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $CAH on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

65X posts · last 7 days
Sep 28Oct 11
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $CAH's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Neutral sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-09-10

$CAH here is really a memecoin community around the 'CAHmunity' and Moontropica game rather than Cardinal Health — thin, celebratory 'CAHmback' posts plus one momentum-scanner tag alongside CNC/VRTX/ADM/COP. No coherent stance either way.

Read what X is saying about $CAH

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $CAH — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersEvent coming upAI verdict · as of 2026-10-03

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Cardinal Health just extended the CVS distribution deal — a quiet healthcare-distribution compounder into Nov 5 earnings.

Cardinal Health is a pharmaceutical-distribution leader (alongside McKesson and AmerisourceBergen/Cencora) whose 2026 story is specific contract-extension execution meeting medical-supply-chain stabilization.

  • The P&L is quietly compounding: Q4 revenue grew 11% YoY to $60.9B at a slim 0.8% operating margin and $1.69 EPS, with trailing EPS beats of 20.2% and 13.6% — these are the kinds of surprises on a razor-thin-margin distribution business that reflect operating-leverage from scale.
  • The specific contract signal is substantive: binding letter of intent to extend pharmaceutical-distribution agreements with CVS Health — this locks in one of the largest customer relationships in the industry, materially reducing contract-renewal risk going into FY27.

At 72% of its 52-week range going into Nov 5 earnings, the setup is positioned for a continuation. A clean operating margin plus the CVS contract-extension revenue commentary is the trigger for a continuation; a soft Specialty segment or any generic-pricing surprise is the invalidation.

What to watch: Nov 5 Q1 earnings — pharmaceutical-distribution revenue growth, Specialty segment, operating margin direction, and CVS-extension specific commentary. Clean margin plus CVS detail is the trigger; Specialty softness is the invalidation.

On the calendar: 2026-11-05 — Q1 earnings

event ahead 30dcontract extension

Read the AI verdict on $CAH

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Healthcare distributor and services company supplying pharmaceuticals, medical products, and specialty logistics to US hospitals and providers.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Distribution sits in its cycle right now — and what that implies for $CAH.

Medical - Distribution · Healthcare

Healthcare supply chain normalization after COVID disruptions is stabilizing distributor margins, while specialty drug distribution (biologics, oncology) is the primary growth segment with higher gross margin per unit than commoditized generics. Group purchasing organization contract cycles and hospital system M&A concentrate purchasing power, pressuring distribution fee structures.

What this means for $CAH

Direct beneficiary — Healthcare distributor and services company supplying pharmaceuticals, medical products, and specialty logistics to US hospitals and providers.

Top industry ETF

$XLVHealth Care Select Sector SPDR
+9.0%YTD
+24.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
36.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
11.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
7.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.2Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-55.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
3.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-3.5Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 11, 2026$2.91$2.42+20.2%
Q1 2026Apr 30, 2026$3.17$2.79+13.6%
Q4 2025Feb 5, 2026$2.63$2.34+12.4%
Q3 2025Oct 30, 2025$2.55$2.18+17.0%
Next earningsThu, Nov 5·consensus EPS $2.95

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q3 FY26$60.9B+11.0%4.1%0.8%$1.69$1.7B
Q2 FY26$65.4B+18.4%3.4%1.1%$1.98$555.0M
Q1 FY26$64.0B+22.4%3.6%1.0%$1.89$865.0M
Q4 FY25$60.2B+0.8%3.7%0.7%$1.00$1.3B

Forward consensus

9-year forecast · up to 13 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$275.6B$270.7B – $281.2B$12.08$11.70 – $12.4512
FY27$265.8B$264.9B – $267.0B$12.54$12.50 – $12.5912
FY27$297.8B$276.4B – $309.2B$13.59$10.53 – $15.5813
FY28$281.7B$275.3B – $289.4B$14.07$13.30 – $14.3212
FY28$320.4B$315.7B – $329.9B$15.44$13.32 – $17.135
FY29$297.4B$283.1B – $321.0B$15.58$14.25 – $17.4511
FY29$339.0B$326.5B – $348.9B$17.71$16.87 – $18.382
FY30$306.5B$299.7B – $315.9B$17.80$17.29 – $18.528
FY31$314.2B$307.2B – $323.9B$20.43$19.84 – $21.258

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.96%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+8.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+15.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 231.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.505-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 19Mary C. SchererChief Accounting Officer2.3K sh$546KSellAug 19Jason M. HollarCEO44.5K sh$10.5MSellAug 18Jason M. HollarCEO80.0K sh$18.9MSellAug 18Stephen M MasonCEO35.0K sh$8.3MSellAug 18Deborah WeitzmanCEO7.4K sh$1.7MSellAug 18Aaron E AltCFO42.0K sh$9.9MSellAug 18Michelle D. GreeneChief Information Officer11.7K sh$2.7MSellAug 18Jessica L MayerChief Legal/Compliance Officer29.4K sh$7.0M
+ 24 other (16 awards · 8 inkinds) in window

See when $CAH insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDOct 18-K — Item 7.01: Press release / Reg FD
AI summary

Cardinal Health, Inc. (CAH) filed a Regulation FD disclosure (8-K Item 7.01) on 2026-10-01. The excerpt shows only the cover page; the actual disclosed material (typically investor presentation slides, a press release, or conference call transcript) is attached as an exhibit. Reg FD events can contain forward-looking statements or updated guidance material to investors.

8-KPress release / Reg FDAug 118-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Cardinal Health, Inc. (CAH) filed an 8-K on August 11, 2026, disclosing its financial results for the fourth quarter and full fiscal year ended June 30, 2026 (Item 2.02). The company's CEO and CFO discussed results and provided a fiscal year 2027 outlook on a webcast held at 8:30 a.m. Eastern the same day, with slide materials available on the investor relations page. Full financial details — including revenue, earnings per share, and segment performance — are contained in the attached Exhibit 99.1 press release rather than the 8-K body. As a major pharmaceutical distribution and healthcare solutions company processing hundreds of billions in drug volume annually, Cardinal Health's fiscal year-end results and forward guidance are closely watched barometers of healthcare supply chain economics.

8-KAgreement terminatedAug 118-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 2.03: Material debt obligation
AI summary

Cardinal Health, Inc. (CAH) entered into a new $4.0 billion unsecured revolving credit facility on August 7, 2026, replacing its existing 364-day revolving credit facility, five-year revolving credit facility, and receivables sale facility program. Wells Fargo serves as Administrative Agent, with BofA, Goldman Sachs, JPMorgan, Barclays, Deutsche Bank, HSBC, PNC, and Bank of Nova Scotia as co-arrangers or documentation agents; the facility runs through August 7, 2031, with up to two one-year extension options. The agreement contains a single financial covenant — a maximum Consolidated Net Leverage Ratio of 4.00x — and will be used for general corporate purposes. For investors, consolidating multiple credit facilities into one larger, longer-dated revolver improves Cardinal Health's liquidity flexibility and simplifies its debt structure as it manages cash flows across its pharmaceutical and specialty businesses.

8-KOfficer or director changeAug 58-K — Item 5.02: Officer or director change
AI summary

Cardinal Health, Inc. (CAH), the Dublin, Ohio healthcare distribution company, filed an 8-K disclosing the appointment of Anita Zielinski as Chief Accounting Officer, effective November 5, 2026. Zielinski, 52, joins from Baxter International where she served as interim CFO and Senior VP/Chief Accounting Officer, and previously spent seven years at Sysco including as SVP/CFO of US Foodservice Operations and as SVP/Chief Accounting Officer. She will join as Senior VP Finance on September 16, 2026, with Mary Scherer continuing as CAO through the November 5 transition date. Compensation includes base salary, annual MIP bonus, long-term equity awards, and a sign-on cash bonus to offset forfeited compensation from her prior employer.

8-KPress release / Reg FDApr 308-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
+ 11 other (3 13Gs · 2 proxys · 2 11-Ks · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Cardinal Health (CAH) Laps the Stock Market: Here's Whyzacks.com·14h ago3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surgezacks.com·17h agoHere's Why Cardinal Health (CAH) is a Strong Growth Stockzacks.com·3d agoAre Medical Stocks Lagging Cardinal Health (CAH) This Year?zacks.com·3d agoShould Value Investors Buy Cardinal Health (CAH) Stock?zacks.com·3d ago

More in Medical - Distribution

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AHG
Voices on X · last 7 days

No standout posts about $CAH on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport